26 Search Results

q=Skin/Cutaneous%20Oncology

Search Again


Brittany Barber , MD, MSc, FRCSC

Email: bbarber1@uw.edu

Dr. Barber's clinical interests include head and neck cancer surgery, robotic surgery, and salivary and endocrine surgery. She has a special interest in reconstructive surgery for skin cancers. Her research interests include quality improvement in free flap reconstruction, peripheral nerve regeneration, cancer genomics, and HPV-related oropharyngeal cancer treatment.

View Bio

Kevin Barry , PhD

Email: kbarry@fredhutch.org

Phone: (206) 667-7811

Dr. Barry aims to determine how innate immune cells recognize cancer and regulate immune responses. He previously identified a novel set of immune cells that regulate immune responses that protect patients from melanoma. The number of these cells in a patient’s tumor can identify those patients who will benefit the most from immunotherapy. Dr. Barry and his team are learning more about the signals that control this set of innate immune cells in cancer. His goal is to generate novel therapies to increase cancer-killing immune responses and save lives from cancer.

View Bio

Shaliender Bhatia , MD

Email: sbhatia@u.washington.edu

Phone: (206) 288-6765

Dr. Bhatia’s research efforts are mostly focused on clinical trials that aim at improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma) and Kidney cancers. He is especially interested in those novel therapeutic approaches that stimulate the immune system against cancer and those that target therapy to the tumors in order to spare unnecessary toxicity.

View Bio

David Byrd , MD

Email: byrd@u.washington.edu

Phone: (206) 543-7512

Dr. Byrd’s clinical interests are in the areas of surgical oncology, endocrine neoplasms (thyroid, parathyroid, adrenal), gastrointestinal and pancreatic cancers, breast cancer, melanoma. His research interests are to study the molecular changes in pancreatic cancer, genetic and clinical studies on melanoma, and lymphatic mapping in breast cancer and melanoma. He is an expert in many surgical procedures, including the Whipple procedure used in pancreas cancer treatment.

View Bio

Marianne Dubard-Gault , MD, MS

Email: mdg2019@uw.edu

Dr. Dubard-Gault is the medical director of the Cancer Genetics Program at SCCA. Her main research interest is to better understand how genetic information influences patients’ decision-making about health care and life choices. She is also interested in exploring ways to help people better access medical genetic information, talk about it with their families and use that knowledge to make decisions that fit their goals.

View Bio

Evan Hall , MD, MPhil

Email: evanh@seattlecca.org

Phone: (206) 606-2496

Dr. Hall's research focuses on how to measure and improve quality of life for patients with cancer. His other areas of interest include physician-patient communication, the health economics of cancer and the benefits of novel modes of patient and caregiver social support, such as online communities.

View Bio

Mark Headley , PhD

Email: mheadley@fredhutch.org

Phone: (206) 667-3619

Dr. Headley is working to understand the cellular and molecular dynamics that underlie tumor metastasis (the spread of cancer cells from a primary tumor to distant organs). The main focus of his lab is to understand how tumor-immune cell interactions variably promote or defend against metastasis. For most cancer patients, metastasis is the leading cause of death. Of particular note, metastasis to the lung is one of the most common and most detrimental sites of tumor spread, and Dr. Headley is especially interested in understanding lung metastasis. He has developed a suite of cutting-edge tools to enable these studies. His lab uses advanced microscopy and surgical techniques to directly visualize tumor cells and immune cells in live lungs in real-time, interrogating the unique lung environment during tumor metastasis with unprecedented detail by pairing this unique microscopy approach with high-resolution single cell profiling. Dr. Headley has recently identified a unique process by which burgeoning metastatic cells shed large cytoplasmic particles from the earliest moments of metastasis. These particles, known as cytoplasts or microparticles, form a platform for engaging a particular class of immune cells called myeloid cells. Notably, during the first hours of metastasis, particular myeloid cells with protumoral properties (macrophages) versus anti-tumoral properties (dendritic cells and patrolling monocytes) encounter and ingest the tumor-derived particles. Dr. Headley seeks to understand how this particular facet of immune-tumor engagement defines anti-tumor immune responses and patient outcomes. His findings will be critical to designing new therapies that can debilitate prometastatic myeloid cell functions while enhancing anti-tumor functions, thereby saving more lives.

View Bio

Masaoki Kawasumi , MD, PhD

Email: kawasumi@uw.edu

Phone: 206-897-5456

Masaoki Kawasumi is a photobiology and skin cancer researcher at the University of Washington in Seattle. Dr. Kawasumi conducts research in skin cancer biology, particularly addressing how cells respond to UV damage and how the DNA damage response can be harnessed to prevent UV-associated skin cancers, the most prevalent cancers in the U.S. The Kawasumi Lab focuses on elucidating molecular mechanisms of UV-mediated diseases (skin cancer and lupus).

View Bio

Teresa Kim , MD

Email: tkim5@uw.edu

Phone: (206) 221-8290

Dr. Kim is a Surgical Oncologist and UW Acting Assistant Professor of Surgery, with expertise in the surgical management of sarcomas, melanomas, and other cancers of the soft tissue, skin, and gastrointestinal tract. Her primary sites of practice are the University of Washington Medical Center, where she operates, and the Seattle Cancer Care Alliance, where she sees patients in clinic. Dr. Kim is a dedicated cancer surgeon who works with a multidisciplinary team of experts to provide individualized and outstanding care. She is also investigating the body’s immune response to cancer and new treatment approaches that combine standard therapies, such as surgery, radiation, and chemotherapy, with novel treatments such as immunotherapy.

View Bio

Yawen Li , PhD

Email: liyw@uw.edu

Phone: (206) 616-8518

Dr. Li is interested in therapeutic and diagnostic radiopharmaceuticals, astatine labeling reagents for small molecule labeling, and developing chemical methods for separation of high specific activity medical radionuclides.

View Bio

Tresa McGranahan , MD, PhD

Email: tresa@uw.edu

Dr. McGranahan is an expert in the care of patients with brain tumors as well as patients with cancer that have spread to the brain or spinal cord from other parts of the body. She also specializes in the effects of cancer and cancer treatments on the nervous system. Her clinical interests are in primary brain tumors, brain metastases, chemotherapy induced neuropathy and paraneoplastic disorders. Her research interests include clinical trials for primary and metastatic brain and spinal tumors.

View Bio

Ata Moshiri , MD, MPH

Email: amoshiri@uw.edu

Dr. Moshiri is the director of the T-VEC (talimogene laherparepvec) program at SCCA. With a background in cutaneous oncology and dermatopathology he is most interested in the genetic alterations that create and perpetuate cancer. Dr. Moshiri also has an interest in pigmented lesions and the use of non-invasive skin imaging to diagnose and monitor lesions.

View Bio

Paul Nghiem , MD, PhD

Email: pnghiem@uw.edu

Phone: (206) 221-2632

Dr. Nghiem’s focus is on skin cancer. He directs a research lab concentrated on basic, clinical and translational research on how sunlight causes skin cancer. A particular emphasis for his patient care and research is Merkel cell carcinoma, a cancer three times more lethal than malignant melanoma. This aggressive skin cancer is typically caused by a recently discovered polyomavirus, and for it to develop it must “escape” from normal immune recognition of this virus. These recent discoveries open exciting avenues of research to improve patient care for those suffering from this disease.

View Bio

Kayode Ojo , PhD

Email: ojo67kk@uw.edu

Phone: (206) 543-0821

The research focus of the Ojo Lab is to develop novel, robust, safe and affordable antimicrobial agents that can withstand the threat of resistance while effectively treating debilitating parasitic diseases. They also have compounds in their drug library that could have an effect on breast, lung, melanoma and prostate cancer cells.

View Bio

Anthony Rongvaux , PhD

Email: rongvaux@fredhutch.org

Phone: (206) 667-7753

Dr. Rongvaux's work focuses on developing models of humanized mice to study the role of the immune system in solid tumor development. His lab is transplanting mice with hematopoietic stem and progenitor cells (CD34+ cells) obtained from bone marrow or peripheral blood after G-CSF mobilization, the tumor from the same patient, and in some cases T cells isolated from peripheral blood of the donor. His team is interested in understanding how infiltrating macrophages affect tumor growth as well as the response to immunotherapies. Most of my work so far has focused on melanoma. We are now also starting projects, with collaborators on the East Coast, on breast and lung cancer.

View Bio

Frank Schmitz , MD, PhD

Email: fschmitz@fredhutch.org

Dr. Schmitz is the Director of Translational and Molecular Medicine for the Chapuis Lab at Fred Hutch. He is working on a personalized anti-tumor vaccine approach, building off previous work in innate immunity and vaccine formulation during his postdocs.

View Bio

Michi Shinohara , MD

Email: mshinoha@uw.edu

Phone: (206) 427-5817

Dr. Shinohara is a dermatologist and dermatopathologist who specializes in medical dermatology, including the care of patients with complex skin disease. She has a special interest in the care of patients with cutaneous lymphomas, and jointly runs a multidisciplinary Cutaneous Lymphoma Clinic at the Seattle Cancer Care Alliance.

View Bio

Andrew Stacey , MD, MSc

Email: awstacey@uw.edu

Phone: (206) 744-2020

Dr. Stacey specializes in cataract surgery and ocular oncology. He sees patients with conjunctival tumors (papilloma, intraepithelial neoplasia, squamous cell carcinoma, melanoma, lymphoma), adult intraocular tumors (iris melanoma, ciliary body melanoma, choroidal melanoma, intraocular metastasis, intraocular lymphoma, retinal angiomas, choroidal hemangiomas, vasoproliferative tumors of the retina), and pediatric intraocular tumors and vascular abnormalities (retinoblastoma, medulloepithelioma, Coats' disease). Dr. Stacey’s research interests include emerging therapeutics for patients with choroidal melanomas, novel statistical approaches to medical research and clinical trial design, telemedicine and new technologies for early diagnosis of ocular tumors, and research into retinoblastoma treatments and outcomes.

View Bio

Robert Stewart , PhD

Email: trawets@uw.edu

Phone: (206) 598-7951

Dr. Stewart's research is focused on biologically guided radiation therapy (BGRT), outcome assessment, and treatment individualization using biological metrics, such as the equivalent uniform dose (EUD) and biologically equivalent dose (BED) concepts.

View Bio